Stuart A. Arbuckle
Director · RHYTHM PHARMACEUTICALS, INC.
Individual
- 2025
- Jun 25, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Stuart A. Arbuckle files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Adage Capital Management, L.P. - $33.20M in PRAX purchases and sales in the last 12 months
- Yvonne Greenstreet - $16.95M in ALNY purchases and sales in the last 12 months
- Jennifer Kayden Lee - $8.90M in RYTM purchases and sales in the last 12 months
- Hunter C. Smith - $8.84M in RYTM purchases and sales in the last 12 months
- Kevin Joseph Fitzgerald - $8.24M in ALNY purchases and sales in the last 12 months
- Yann Mazabraud - $6.62M in RYTM purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Stuart A. Arbuckle?
Stuart A. Arbuckle is a corporate insider, tracked as Director of RHYTHM PHARMACEUTICALS, INC. (RYTM). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Stuart A. Arbuckle last file a Form 4?
The most recent primary Form 4 on record is dated 25 June 2026, one of 5 filings going back to 2025.
